Search results
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...
Investing.com· 7 days agoIn their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...
AstraZeneca PLC ADR TradeGate Stock Price Today | NASDAQ AZNPy Live Ticker - Investing.com
Investing.com· 18 hours agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
New antibiotic based on AstraZeneca drugs kills off deadly bacteria, spares the good guys
FierceBiotech· 6 days agoA new antibiotic based on drugs developed by AstraZeneca can kill off dangerous bacteria that cause...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 4 days agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 4 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
Compugen hits milestone with AstraZeneca cancer trial By Investing.com
Investing.com· 7 days agoThe trial is a crucial step in evaluating the drug as a first-line treatment for a specific type of...
Patient’s Dark Fantasy About Aetna Lands Him in Jail
The Daily Beast via Yahoo News· 2 days agoMany Americans loathe their health insurance providers.A majority say they have severe concerns about financial hardship due to medical bills—even with...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 4 days agoAstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months...
Move over 'Magnificent 7,' the 'Fantastic 5' may offer higher earnings and return potential
CNBC· 1 hour agoLooking for a less risky way to find growth stocks amid all the artificial intelligence hype?...